{"filing":{"accession_number":"0001193125-26-306689","cik":"0001121404","ticker":"SNYNF","company_name":"Sanofi","form":"6-K","filing_date":"2026-07-17","report_date":null,"primary_document":"d106024d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526306689/d106024d6k.htm"},"events":[{"id":18549,"run_id":16675,"accession_number":"0001193125-26-306689","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces FDA approval of Sarclisa Escena (isatuximab-irfc) subcutaneous formulation with an on-body injector (CirCLIQ OBI), representing a significant product innovation and regulatory milestone for Sanofi's oncology franchise. The approval expands the delivery options for an existing drug across multiple approved indications in multiple myeloma treatment, supported by the pivotal IRAKLIA phase 3 study demonstrating non-inferiority to IV formulation. While not a discrete M\u0026A, debt, or governance event, this regulatory approval of a novel delivery mechanism for a cornerstone oncology product materially affects the commercial potential and competitive positioning of Sarclisa, which has already been prescribed to over 70,000 patients worldwide.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-07-17","form":"6-K","submitted_at":null,"items":[{"id":17391,"accession_number":"0001193125-26-306689","item_number":"EX-99.1","item_title":"d106024dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA approval of Sarclisa Escena (isatuximab-irfc) subcutaneous formulation with an on-body injector (CirCLIQ OBI), representing a significant product innovation and regulatory milestone for Sanofi's oncology franchise. The approval expands the delivery options for an existing drug across multiple approved indications in multiple myeloma treatment, supported by the pivotal IRAKLIA phase 3 study demonstrating non-inferiority to IV formulation. While not a discrete M\u0026A, debt, or governance event, this regulatory approval of a novel delivery mechanism for a cornerstone oncology product materially affects the commercial potential and competitive positioning of Sarclisa, which has already been prescribed to over 70,000 patients worldwide.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-17T10:06:48.990425+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17391,"accession_number":"0001193125-26-306689","item_number":"EX-99.1","item_title":"d106024dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA approval of Sarclisa Escena (isatuximab-irfc) subcutaneous formulation with an on-body injector (CirCLIQ OBI), representing a significant product innovation and regulatory milestone for Sanofi's oncology franchise. The approval expands the delivery options for an existing drug across multiple approved indications in multiple myeloma treatment, supported by the pivotal IRAKLIA phase 3 study demonstrating non-inferiority to IV formulation. While not a discrete M\u0026A, debt, or governance event, this regulatory approval of a novel delivery mechanism for a cornerstone oncology product materially affects the commercial potential and competitive positioning of Sarclisa, which has already been prescribed to over 70,000 patients worldwide.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-17T10:06:48.990425+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-07-17"}]}